צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 2220 fentanyl - transdermální náplast - 100mcg/h - fentanyl

צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 2220 fentanyl - transdermální náplast - 12mcg/h - fentanyl

צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 2220 fentanyl - transdermální náplast - 25mcg/h - fentanyl

צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 2220 fentanyl - transdermální náplast - 50mcg/h - fentanyl

צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 2220 fentanyl - transdermální náplast - 75mcg/h - fentanyl

האיחוד האירופי - צ׳כית - EMA (European Medicines Agency)

janssen-cilag international nv - ceftobiprole medocaril - skin diseases, infectious; soft tissue infections

צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 10236 epoetin alfa - injekční roztok v předplněné injekční stříkačce - 200iu/0,1ml - erytropoetin

צ׳כיה - צ׳כית - SUKL (Státní ústav pro kontrolu léčiv)

janssen-cilag s.r.o., praha array - 10236 epoetin alfa - injekční roztok v předplněné injekční stříkačce - 400iu/0,1ml - erytropoetin

האיחוד האירופי - צ׳כית - EMA (European Medicines Agency)

janssen pharmaceutica n.v. - mitratapid - preparáty proti obezitě, diety - psi - jako pomoc při léčbě nadváhy a obezity u dospělých psů. používá se jako součást celkového programu řízení hmotnosti, který zahrnuje také vhodné dietní změny. představujeme vhodné změny životního stylu (např. zvýšené cvičení) v kombinaci s tímto programem řízení hmotnosti může poskytnout další výhody.

האיחוד האירופי - צ׳כית - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infekce - antivirotika pro systémové použití - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.